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ORIGINAL ARTICLE VIROLOGYCorticosteroids for the treatment of human infection with inﬂuenza virus:
a systematic review and meta-analysisJ.-W. Yang1,2, L.-C. Fan2, X.-Y. Miao2, B. Mao1,2, M.-H. Li1,2, H.-W. Lu2, S. Liang2 and J.-F. Xu1,2
1) Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai and 2) Department of
Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Soochow University, Suzhou, ChinaAbstractAdministration of corticosteroids to patients affected by inﬂuenza virus, especially pandemic avian inﬂuenza virus, although relatively
common, remains controversial. A systematic review and meta-analysis was performed to assess the impact of corticosteroid treatment
on outcomes of patients with inﬂuenza virus infection. The PubMed, EMBASE, Web of Science and Cochrane Library databases were
searched up to February, 2015. Studies comparing corticosteroid treatment with no corticosteroid treatment in patients with inﬂuenza
virus infection were included. The primary outcomes assessed were the association of mortality and nosocomial infection with
corticosteroid treatment. Two authors independently extracted the data. ORs and weighted mean differences (WMDs) were used to
describe dichotomous data and continuous data, respectively. Nineteen studies with 4916 patients were included in this meta-analysis.
The results showed that corticosteroid treatment was signiﬁcantly associated with mortality (OR 1.98, 95% CI 1.62–2.43, p < 0.00001)
and nosocomial infection (OR 3.16, 95% CI 2.09–4.78, p < 0.00001). The durations of mechanical ventilation (WMD 3.82, 95% CI
1.49–6.15, p 0.001) and intensive-care unit stay (WMD 4.78, 95% CI 2.27–7.29, p 0.0002) were both markedly longer in the
corticosteroid treatment group than in the control group. These ﬁndings suggest that routine steroid use may not be ideal for inﬂuenza
virus infection. However, these results are derived from observational studies, with some important biases. They should be examined in
future sufﬁciently powered randomized trials.
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E-mail: jfxucn@gmail.comIntroductionInﬂuenza virus is a common pathogen affecting the respiratory
system. Complications described in the 2009 inﬂuenza A
(H1N1) pandemic included rapidly developing viral pneumonia,
acute respiratory distress syndrome (ARDS), renal failure, andMicrobiol Infect 2015; 21: 956–963
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.022neurological symptoms, as in the 2004 inﬂuenza A (H5N1)
pandemic, which led to high intensive-care unit (ICU) occu-
pancy and mortality rates [1–4]. The WHO reported that the
mortality rate of the 2004–2005 inﬂuenza A (H5N1) pandemic
was approximately 61%, and the in-hospital mortality of the
2009 inﬂuenza A H1N1 pandemic ranged from 17.4% to 46% in
different locations [1–7].
Oseltamivir might improve survival and reduce the number
of days of hospitalization among patients with severe inﬂuenza
requiring hospitalization, especially if administered within 48 h
of the onset of symptom [2,8–11]. Steroids may play a role in
inhibiting inﬂammation. The inﬂammatory cascade of
community-acquired pneumonia can be blocked by the
administration of systemic corticosteroid treatment [12,13].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Yang et al. Corticosteroids for inﬂuenza virus infection 957Despite persistent controversy, steroids were given as anti-
inﬂammatory treatment to patients with severe inﬂuenza
pneumonia. Recently, several studies have suggested that ste-
roids may be associated with worse outcomes in patients with
inﬂuenza [14–16]. This may be related to persistent viral
shedding, replication, and delays in clearance [17].
A systematic review and meta-analysis of studies on corti-
costeroid use in patients with inﬂuenza was performed. The
effects of corticosteroid treatment on survival and other clinical
outcomes of these patients were investigated.Materials and methodsThe systematic review included studies fulﬁlling the following
inclusion criteria: (a) they were randomized control trials or
observational studies; (b) they were performed on patients with
conﬁrmed or suspected inﬂuenza virus infection; (c) the expo-
sure group used corticosteroids and the comparison group did
not; and (d) the outcomes were mortality, nosocomial infection,
or other clinical outcomes. A study was excluded if (a) it was a
review article or expert opinion, (b) all subjects were immu-
nocompromised patients, or (c) no outcome data were available.
The primary outcomes were mortality and nosocomial
infection. The secondary outcomes included speciﬁc bacteria
causing nosocomial infections, duration of mechanical ventila-
tion (MV), duration of ICU stay, and duration of ICU stay
among surviving patients.
The PubMed, EMBASE, Web of Science and Cochrane Li-
brary databases were comprehensively searched from incep-
tion to 28 February 2015 by two investigators. The search
terms were ‘inﬂuenza’ and ‘corticosteroid’ or ‘steroid’ or
‘dexamethasone’ or ‘methylprednisolone’ or ‘hydrocortisone’
or ‘prednisolone’. The references of eligible studies were
searched. Two authors independently searched for the studies
that met the inclusion criteria.
The quality of each study was assessed by two authors
independently according to the Newcastle–Ottawa Scale
(NOS), which was used for non-randomized controlled studies.
There are three domains in the NOS score: (a) ‘selection bias’,
containing four items; (b) ‘comparability bias’, containing two
items; and (c) ‘outcome bias’, containing three items [18]. The
speciﬁc content of the NOS is detailed in Table S1.
Unadjusted and adjusted outcome data were extracted from
observational studies by two individuals. In each study, several
characteristics were recorded, including study location, period,
design, targeted population, drugs selected, and dose. Dis-
crepancies were resolved by consensus.
Meta-analysis was performed with Review Manager software
(version 5.2; Cochrane Collaboration, Oxford, UK). ORs andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyweighted mean differences (WMDs) were used to describe
dichotomous data and continuous data, respectively. Cochran’s
χ2 test and the the I2 test for inconsistency were used to es-
timate study heterogeneity. I2 > 50% indicated signiﬁcant het-
erogeneity, in which case a random-effects model was selected
[19]. Otherwise, a ﬁxed-effect model was used. Adjusted effect
estimates (where reported) were summarized by the use of
inverse variance analysis. If substantial heterogeneity was found,
subgroup analysis according to ICU and non-ICU patient care
was performed to assess heterogeneity. We deﬁned the place
of patients receiving treatment according to the descriptions in
the original studies.ResultsThe initial search identiﬁed 2797 potentially relevant studies.
After screening of the titles and abstracts, 2376 articles were
excluded because of irrelevance or redundancy. Of 421 full-text
articles reviewed, 402 were excluded for various reasons. Ul-
timately, 19 studies comprising 4916 patients were included in
this meta-analysis [1,3,6,10,11,14–16,20–30]. The details of the
screening process are shown in Fig. 1.
The characteristics of the included studies are summarized in
Table 1 and Table S2. The studies were published between
2004 and February 2015. Four studies described the effects of
corticosteroid treatment on H5N1 infection [10,20–22], 13
studies described H1N1 infection [1,3,6,11,14–16,23–28], one
study described H7N9 infection [29], and one study described
seasonal inﬂuenza and inﬂuenza A(H1N1)pdm09 virus infection
[30]. Dexamethasone, methylprednisolone and hydrocortisone
were the corticosteroids used for patients with inﬂuenza virus
infection.
All studies included in this meta-analysis were observational
studies. Selection bias was inevitable. However, in all studies,
the exposure group and comparison group originated from the
same population. Eighty-four per cent (16/19) of studies had
comparability bias, because there was a tendency for cortico-
steroids to be used in more severely ill patients, which was also
the main source of bias for our study. None of the studies had
outcome bias, as data were extracted from reliable medical
records, follow-up time was sufﬁcient, and only a small number
of patients were lost to follow-up in each study. All studies
were given ﬁve or more NOS stars, indicating high quality [18].
The details are given in Table S3.
Primary outcomes
Seventeen studies reported the association between cortico-
steroid use and mortality [1,3,6,10,14–16,20–23,25–30].
Because of heterogeneity in the timing of mortality reported inand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 956–963
FIG. 1. Flow diagram.
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Therefore, mortality was considered as reported in the indi-
vidual studies. The pooled results showed that systemic corti-
costeroid use was signiﬁcantly associated with mortality (OR
1.98, 95% CI 1.62–2.43, p <0.00001, I2 = 9%) (Fig. 2a). Seven
studies included in this meta-analysis reported an adjusted effect
estimate (OR or hazard ratio (HR)) [14–16,22,25,28,30], and
similar results were obtained (adjusted HR 1.77, 95% CI
1.40–2.23, I2 = 40%) (Fig. 2b). Subgroup analysis showed both
ICU mortality (OR 1.79, 95% CI 1.36–2.36, I2 = 55%) and non-
ICUmortality (OR 2.24, 95% CI 1.66–3.03, I2 = 0%) to be higher
in patients using corticosteroids than in controls (Fig. S1). TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectstudy of Diaz et al. in the ICU subgroup, which showed no sig-
niﬁcant difference between groups, contributed to the sub-
stantial heterogeneity. In contrast to the mixed patients in other
studies, the patients in this study all had conﬁrmed inﬂuenza
pneumonia, and there were more asthma patients in the corti-
costeroid group. In addition, early corticosteroid use (in the ﬁrst
3 days of treatment initiation) was signiﬁcantly associated with
mortality (OR 2.21, 95% CI 1.64–2.96, I2 = 0%) (Fig. S2). Six
studies contributed to the meta-analysis of nosocomial infection
[11,14–16,23,30], the rate of which was signiﬁcantly higher in
patients given corticosteroid treatment than in controls (OR
3.16, 95% CI 2.09–4.78, p <0.00001, I2 = 57%) (Fig. 3). Thereious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 956–963
TABLE 1. Characteristics of included studies
Reference Study date Location Virus Severity No. of patients Drug and dose equivalent Duration Study type
Xi et al. [1] 1 October 2009 to 23 December 2009 Beijing H1N1 Hospital 155 MP 80 (80–160) mg/day NR RS
Jain et al. [3] April 2009 to 20 June 2009 US H1N1 Hospital 239 NR NR RS
Perez-Padilla et al. [6] 24 March 2009 to 24 April 2009 Mexico H1N1 Hospital 18 HYD 300 mg/day or MP 60 mg/day NR RS
Kandun et al. [10] June 2005 to October 2005 Indonesian H5N1 Hospital 8 DEX NR or MP NR NR RS
Chien et al. [11] 2 July 2009 to 29 August 2009 Taiwan H1N1 Hospital 96 HYD <300 mg/day or MP 2 mg/day NR RS
Martin-Loeches et al. [14] 23 June 2009 to 11 February 2010 Europe H1N1 ICU 220 MP >240 mg/day or PDN >30 mg/day 10.3 ± 11.7 days POMS
Brun-Buisson et al. [15] 1 September 2009 to 1 March 2010 French H1N1 ARDS/ICU 208 HYD 270 (200–400) mg/day 11 (6–20) days RS
Kim et al. [16] September 2009 to February 2010 South Korea H1N1 ICU 245 PDN 75 mg/day 6 (3–14) days RS
Chotpitayasunondh et al. [20] 1 January 2004 to 31 March 2004 Thailand H5N1 Hospital 12 NR NR RS
Hien et al. [21] January 2004 to July 2005 Vietnam H5N1 Hospital 29 MP median 80 mg/day NR RS
Liem et al. [22] 1 January 2004 to 31 December 2006 Vietnam H5N1 Hospital 67 MP 1–3 mg/kg/day Up to 7 days RS
Viasus et al. [23] 12 June 2009 to 10 November 2009 Spain H1N1 Hospital 166 HYD >300 mg/day 9 (5–13.5) days POCS
Kudo et al. [24]2012 August 2009 to March 2010 Japan H1N1 Hospital 58 MP 2–6 mg/kg/day (<15 years) or
80–320 mg/day (>15 years)
Median 5.2 days RS
Han et al. [25] 20 October 2009 to 30 November 2009 Shenyang China H1N1 Hospital 83 MP median 50 mg/day
MP median 61 mg/day
NR RS
Chawla et al. [26] October 2009 to December 2010 India H1N1 ICU 77 NR 10.61 ± 7.84 days RS
Rodríguez et al. [27] Winter of 2010–2011 Spain H1N1 ICU 200 HYD NR 7 (5–10) days POMS
MP NR
Diaz et al. [28] 2009 Spain H1N1 ICU 372 NR 11.22 ± 16.25 days POMS
Hu et al. [29] 4 April 2013 to 20 April 2013 Shanghai, China H7N9 Hospital 14 MP 40–120 mg/day Median 7.5 days RS
Lee et al. [30] 2008–2011 Hong Kong
Singapore
Beijing
Variousa Hospital 2649 MP NR
PDN NR
HYD NR
NR POMS
Data on dose and duration are presented as the mean ± standard deviation or median (interquartile range).
ARDS, acute respiratory distress syndrome; DEX, dexamethasone; HYD, hydrocortisone; ICU, intensive-care unit; MP, methylprednisolone; NR, not reported; PDN, prednisone; POCS, prospective, observational cohort study; POMS, prospective
observational multicentre study; RS, retrospective study.
aSeasonal inﬂuenza A/B viruses and inﬂuenza A(H1N1)pdm09 virus.
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FIG. 2. Association between corticosteroid use and mortality. (a) Unadjusted results. (b) Adjusted outcomes ORs or hazard ratios for mortality. d.f.,
degrees of freedom; IV, inverse variance; SE, standard error.
960 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIwas signiﬁcant heterogeneity in this comparison and the study of
Brun-Buisson et al. was outlier, which showed no signiﬁcant
difference between groups. All subjects in this study were pa-
tients with ARDS, who might have been prone to superinfec-
tions regardless of steroid treatment. Investigation of common
bacteria causing nosocomial infections revealed Acinetobacter
baumannii (OR 4.21, 95% CI 2.04–8.65, p <0.0001), Pseudo-
monas aeruginosa (OR 5.48, 95% CI 1.80–16.69, p 0.003) and
Klebsiella pneumoniae (OR 2.94, 95% CI 1.02–8.52, p 0.05) to be
signiﬁcantly more common in the corticosteroid treatment
group (Table S4).
Secondary outcomes
Corticosteroid treatment was associated with longer durations
of MV (WMD 3.82, 95% CI 1.49–6.15, p 0.001, I2 = 0%) and
ICU stay (WMD 4.78, 95% CI 2.27–7.29, p 0.0002, I2 = 0%) inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcritically ill patients (Table 2). However, the duration of ICU
stay for surviving patients (WMD 3.04, 95% CI –0.24 to 6.31, p
0.07, I2 = 0%) was non-signiﬁcantly longer with corticosteroid
treatment (Table 2).DiscussionThe results of this study indicate that corticosteroid treatment
is signiﬁcantly associated with mortality (adjusted HR 1.77, 95%
CI 1.40–2.23). Subgroup analysis showed that the mortality
rate is higher in patients receiving corticosteroid treatment,
both among patients hospitalized in the ICU and among those
outside the ICU (Fig. S1). Our study provides no evidence of a
beneﬁcial effect of corticosteroids in ICU patients or non-ICU
patients.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 956–963
FIG. 3. Association between corticosteroid use and nosocomial infection. d.f., degrees of freedom; IV, inverse variance; SE, standard error.
TABLE 2. Clinical outcomes of patients treated with or without corticosteroid therapy
Outcome measures No. of studies No. of patients WMD (95% CI) p
Test for
heterogeneity
I2 (%) p
Length of MV 2 453 3.82 (1.49–6.15) 0.001 0 0.9
Length of ICU stay 2 453 4.78 (2.27–7.29) 0.0002 0 0.92
Length of survivor ICU stay 2 304 3.04 (–0.24 to 6.31) 0.07 0 0.42
ICU, intensive-care unit; MV, mechanical ventilation; WMD, weighted mean difference.
CMI Yang et al. Corticosteroids for inﬂuenza virus infection 961Several studies reported that corticosteroid use was asso-
ciated with an increased risk of superinfections [14–16]. Our
results are consistent with this, showing that the incidence of
nosocomial infection is signiﬁcantly higher after corticosteroid
treatment (OR 3.16, 95% CI 2.09–4.78, p <0.00001, I2 = 57%).
This may be because corticosteroid treatment increases viral
shedding, replication, and delay in clearance, leading to the
further wearing down of host defences. Also, corticosteroids
have an effect on the immune function of macrophages and
granulocytes, which are the main host cells involved in defence
against pathogenic organisms [14]. Baseline patient character-
istics (such as ARDS), different study settings and various tim-
ings, doses or durations of corticosteroid used in different
studies may explain the heterogeneity in the meta-analysis.
A. baumannii, P. aeruginosa and K. pneumoniae were more
common in the corticosteroid group.
Recently, two randomized control trials have shown that
corticosteroid use can reduce the incidence of treatment failure
and shorten the time to clinical stability in patients with
community-acquired pneumonia [12,13]. Apparently, this does
not apply to patients with severe inﬂuenza virus infection. Our
results revealed that steroid treatment prolonged the durations
of MV and ICU stay. The effect of steroid use on oxygenation
could not be subjected to meta-analysis, owing to the diversity
of data. Several studies reported that systemic corticosteroid
treatment had no discernible inﬂuence on the improvement in
blood oxygen saturation of patients with severe inﬂuenza. More
oxygen was supplied to the steroid group, but steroids tendedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyto be given to the more severely ill patients, which may be the
reason for this ﬁnding [15,16,24].
Brun-Buisson et al. reported that early administration of
corticosteroids remained signiﬁcantly associated with death,
whereas later administration was not [15]. Owing to insufﬁ-
cient data, subgroup analysis of corticosteroid effect accord-
ing to early and late use could not be performed. However,
our ﬁndings indicated that early corticosteroid use (in the ﬁrst
3 days of therapy initiation) was strongly associated with
mortality as compared with no corticosteroid use. It is
possible that very early corticosteroid administration favours
persistent viral replication and limits host defences against
future infections. Nevertheless, the current results do not
exclude the possibility that corticosteroid treatment could
have a less detrimental effect or even be beneﬁcial at a later
stage, when viral replication is controlled by early antiviral
treatment. In addition, Xi et al. reported that patients treated
with a low daily dose of corticosteroids had a mortality rate
similar to that of those treated with a high daily dose [1].
However, the results of studies on dosing or duration of
corticosteroid treatment are diverse. Thus, investigation of a
possible beneﬁt of corticosteroid therapy with different tim-
ings, doses and durations could not be performed. Further
studies are needed to address such important clinical issues
and to develop better treatment regimens for patients with
inﬂuenza virus infection.
The present study has several possible limitations. First, all
studies included in this review are observational studiesand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 956–963
962 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIcontaining many confounding factors, so that selection bias and
comparability bias probably affect the quality of meta-analysis,
although the studies included in this meta-analysis score rela-
tively high on the NOS score, and the adjusted effect estimates
concord with the crude results. Second, because of heteroge-
neity in the reporting of timing of mortality among these
studies, stratiﬁcation by certain time-point mortality was not
possible. Third, subgroup analysis according to doses of steroid
received, early or late steroid use or other factors cannot be
performed. Finally, there is overlap in some studies, so that a
small number of the enrolled patients may have been counted
more than once. Attempts were made to contact authors for
necessary information. If this information was not provided,
studies from different researcher teams, and with different
designs, were treated as independent research.ConclusionThe results of our review show that corticosteroid treatment
for patients with inﬂuenza virus infection does not result in
better outcomes, and may be associated with mortality and
nosocomial infections. Moreover, durations of MV and ICU stay
are clearly longer in patients who receive systemic cortico-
steroid treatment. Although these data are derived from
observational studies, with important limitations, these results
suggest that physicians should be very cautious when consid-
ering corticosteroid treatment in patients with inﬂuenza virus
infection. Further in-depth studies with strong designs and
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